JP6600637B2 - 膵臓がんを決定するための方法、アレイおよびそれらの使用 - Google Patents
膵臓がんを決定するための方法、アレイおよびそれらの使用 Download PDFInfo
- Publication number
- JP6600637B2 JP6600637B2 JP2016552704A JP2016552704A JP6600637B2 JP 6600637 B2 JP6600637 B2 JP 6600637B2 JP 2016552704 A JP2016552704 A JP 2016552704A JP 2016552704 A JP2016552704 A JP 2016552704A JP 6600637 B2 JP6600637 B2 JP 6600637B2
- Authority
- JP
- Japan
- Prior art keywords
- expression
- measuring
- alternative
- additional embodiment
- pancreatic cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6813—Hybridisation assays
- C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54386—Analytical elements
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
- G01N33/581—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1319878.3A GB201319878D0 (en) | 2013-11-11 | 2013-11-11 | Method, Array and use thereof |
| GB1319878.3 | 2013-11-11 | ||
| PCT/GB2014/053340 WO2015067969A2 (en) | 2013-11-11 | 2014-11-11 | Method, array and use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016537652A JP2016537652A (ja) | 2016-12-01 |
| JP2016537652A5 JP2016537652A5 (enExample) | 2017-12-07 |
| JP6600637B2 true JP6600637B2 (ja) | 2019-10-30 |
Family
ID=49818441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016552704A Expired - Fee Related JP6600637B2 (ja) | 2013-11-11 | 2014-11-11 | 膵臓がんを決定するための方法、アレイおよびそれらの使用 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20160252513A1 (enExample) |
| EP (1) | EP3069143B1 (enExample) |
| JP (1) | JP6600637B2 (enExample) |
| KR (1) | KR102240473B1 (enExample) |
| CN (1) | CN105917230B (enExample) |
| AU (1) | AU2014345484B2 (enExample) |
| BR (1) | BR112016010510A2 (enExample) |
| CA (1) | CA2930211A1 (enExample) |
| ES (1) | ES2704888T3 (enExample) |
| GB (1) | GB201319878D0 (enExample) |
| MX (1) | MX2016006125A (enExample) |
| WO (1) | WO2015067969A2 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2442919T3 (es) | 2007-03-27 | 2014-02-14 | Immunovia Ab | Firma/marcadores de proteínas para la detección de adenocarcinoma |
| GB201014837D0 (en) | 2010-09-07 | 2010-10-20 | Immunovia Ab | Biomarker signatures and uses thereof |
| GB201103726D0 (en) | 2011-03-04 | 2011-04-20 | Immunovia Ab | Method, array and use thereof |
| CN105021825B (zh) * | 2015-07-09 | 2016-08-17 | 陈勇 | 一种检测胰腺癌相关多肽dap44的elisa试剂盒 |
| GB201516801D0 (en) | 2015-09-22 | 2015-11-04 | Immunovia Ab | Method, array and use thereof |
| GB201608192D0 (en) | 2016-05-10 | 2016-06-22 | Immunovia Ab | Method, array and use thereof |
| GB201609950D0 (en) * | 2016-06-07 | 2016-07-20 | Immunovia Ab | Biomarkers signatures and uses thereof |
| GB201609951D0 (en) * | 2016-06-07 | 2016-07-20 | Immunovia Ab | Biomarkers signatures and uses thereof |
| EP4053557A1 (en) * | 2016-11-24 | 2022-09-07 | Huvet Bio, Inc. | Il-29 as a marker for a pancreatic disease |
| GB201701572D0 (en) | 2017-01-31 | 2017-03-15 | Immunovia Ab | Methods, arrays and uses thereof |
| KR102536314B1 (ko) * | 2018-05-23 | 2023-05-25 | 주식회사 휴벳바이오 | 질환의 진단용 조성물 |
| US11487739B2 (en) | 2019-02-19 | 2022-11-01 | Nasdaq, Inc. | System and methods for data model detection and surveillance |
| CA3138991A1 (en) * | 2019-05-02 | 2020-11-05 | Ligandal, Inc. | Methods and compositions for diagnostically-responsive ligand-targeted delivery of therapeutic agents |
| EP3974541A4 (en) * | 2019-05-21 | 2023-10-11 | Acurasysbio Co., Ltd. | COMPOSITION FOR CANCER DIAGNOSIS |
| GB202010970D0 (en) | 2020-07-16 | 2020-09-02 | Immunovia Ab | Methods, arrays and uses thereof |
| KR102226826B1 (ko) * | 2020-08-06 | 2021-03-11 | 주식회사 휴벳바이오 | 버피 코트 시료에 사용하기 위한 췌장암 진단용 조성물 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3169789D1 (en) | 1980-05-02 | 1985-05-15 | Edward P Davis | Leg aid device |
| US4486530A (en) | 1980-08-04 | 1984-12-04 | Hybritech Incorporated | Immunometric assays using monoclonal antibodies |
| US4376110A (en) | 1980-08-04 | 1983-03-08 | Hybritech, Incorporated | Immunometric assays using monoclonal antibodies |
| US5856090A (en) | 1994-09-09 | 1999-01-05 | The Scripps Research Institute | DNA-methylase linking reaction |
| GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
| US6727066B2 (en) * | 2000-07-28 | 2004-04-27 | Incyte Corporation | Genes expressed in treated human C3A liver cell cultures |
| AU2003230838A1 (en) * | 2002-04-05 | 2003-10-27 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of | Methods of diagnosing potential for metastasis or developing hepatocellular carcinoma and of identifying therapeutic targets |
| DE60325628D1 (de) * | 2002-09-30 | 2009-02-12 | Oncotherapy Science Inc | Gene und polypeptide in verbindung mit menschlichen pankreaskarzinomen |
| US7250496B2 (en) * | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
| US7790867B2 (en) * | 2002-12-05 | 2010-09-07 | Rosetta Genomics Inc. | Vaccinia virus-related nucleic acids and microRNA |
| AU2004255216B2 (en) * | 2003-07-01 | 2010-08-19 | Immunomedics, Inc. | Multivalent carriers of bi-specific antibodies |
| CN102344493B (zh) * | 2004-05-28 | 2014-09-03 | 艾更斯司股份有限公司 | 结合于psca蛋白的用于癌症诊断的抗体 |
| US8383357B2 (en) * | 2005-03-16 | 2013-02-26 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to epidermal growth factor receptor kinase inhibitors |
| WO2006110585A2 (en) * | 2005-04-07 | 2006-10-19 | Novartis Vaccines And Diagnostics Inc. | Cancer-related genes (prlr) |
| JP2007051880A (ja) * | 2005-08-15 | 2007-03-01 | Tokyo Univ Of Science | 膵臓癌の検出方法、膵臓癌の診断キット |
| NZ593224A (en) * | 2006-01-11 | 2012-10-26 | Genomic Health Inc | Gene expression markers (fap) for colorectal cancer prognosis |
| ES2442919T3 (es) * | 2007-03-27 | 2014-02-14 | Immunovia Ab | Firma/marcadores de proteínas para la detección de adenocarcinoma |
| KR20120087885A (ko) * | 2007-06-29 | 2012-08-07 | 안국약품 주식회사 | 난소암의 예측 마커 |
| JP2011516826A (ja) * | 2008-03-07 | 2011-05-26 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 間葉系様腫瘍細胞またはこの形成を阻害する作用剤の同定のための方法 |
| GB0815846D0 (en) * | 2008-09-01 | 2008-10-08 | Immunovia Ab | diagnosis, prognosis and imaging of disease |
| CN104535765A (zh) * | 2009-03-12 | 2015-04-22 | 癌症预防和治疗有限公司 | 鉴定、评估、预防以及治疗肺疾病的方法及试剂盒 |
| US20120264634A1 (en) * | 2009-09-29 | 2012-10-18 | Protagen Aktiengesellschaft | Marker Sequences for Pancreatic Cancer Diseases, Pancreatic Carcinoma and Use Thereof |
| MY185582A (en) * | 2010-01-07 | 2021-05-24 | Malaysian Palm Oil Board | Anti-obesity and anti-dyslipidemic effects of oil palm phenolics in preventing atheroslerosis and cardiovascular disease |
| CN102279264A (zh) * | 2010-06-09 | 2011-12-14 | 李彬 | 48种恶性肿瘤标志物抗体芯片的制备方法 |
| WO2012021407A2 (en) * | 2010-08-13 | 2012-02-16 | Morehouse School Of Medicine | Biomarkers for stroke |
| GB201103726D0 (en) * | 2011-03-04 | 2011-04-20 | Immunovia Ab | Method, array and use thereof |
| WO2012139628A1 (en) * | 2011-04-11 | 2012-10-18 | Lykera Biomed Sa | Coding polypurine hairpins for the treatment of cancer |
-
2013
- 2013-11-11 GB GBGB1319878.3A patent/GB201319878D0/en not_active Ceased
-
2014
- 2014-11-11 CN CN201480071589.2A patent/CN105917230B/zh not_active Expired - Fee Related
- 2014-11-11 KR KR1020167015574A patent/KR102240473B1/ko not_active Expired - Fee Related
- 2014-11-11 ES ES14815406T patent/ES2704888T3/es active Active
- 2014-11-11 EP EP14815406.5A patent/EP3069143B1/en not_active Not-in-force
- 2014-11-11 AU AU2014345484A patent/AU2014345484B2/en not_active Ceased
- 2014-11-11 MX MX2016006125A patent/MX2016006125A/es unknown
- 2014-11-11 JP JP2016552704A patent/JP6600637B2/ja not_active Expired - Fee Related
- 2014-11-11 CA CA2930211A patent/CA2930211A1/en not_active Abandoned
- 2014-11-11 WO PCT/GB2014/053340 patent/WO2015067969A2/en not_active Ceased
- 2014-11-11 BR BR112016010510A patent/BR112016010510A2/pt not_active IP Right Cessation
- 2014-11-11 US US15/035,953 patent/US20160252513A1/en not_active Abandoned
-
2018
- 2018-10-16 US US16/161,741 patent/US20190128891A1/en not_active Abandoned
-
2022
- 2022-03-25 US US17/704,057 patent/US20220214344A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20160085327A (ko) | 2016-07-15 |
| US20190128891A1 (en) | 2019-05-02 |
| MX2016006125A (es) | 2016-08-12 |
| CN105917230A (zh) | 2016-08-31 |
| AU2014345484B2 (en) | 2020-08-27 |
| ES2704888T3 (es) | 2019-03-20 |
| GB201319878D0 (en) | 2013-12-25 |
| EP3069143A2 (en) | 2016-09-21 |
| CA2930211A1 (en) | 2015-05-14 |
| CN105917230B (zh) | 2020-06-16 |
| US20160252513A1 (en) | 2016-09-01 |
| EP3069143B1 (en) | 2018-10-10 |
| JP2016537652A (ja) | 2016-12-01 |
| AU2014345484A1 (en) | 2016-06-30 |
| KR102240473B1 (ko) | 2021-04-15 |
| WO2015067969A2 (en) | 2015-05-14 |
| WO2015067969A3 (en) | 2015-08-06 |
| US20220214344A1 (en) | 2022-07-07 |
| BR112016010510A2 (pt) | 2017-12-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220214344A1 (en) | Method, array and use thereof | |
| US20200088742A1 (en) | Method, array and use for determining the presence of pancreatic cancer | |
| JP6465902B2 (ja) | 腺癌の検出のための蛋白質シグネチャー/マーカー | |
| JP6104796B2 (ja) | 方法、アレイ、およびこれらの使用 | |
| CA2706786A1 (en) | Diagnostic methods and arrays for use in the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20171025 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20171025 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20181016 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190109 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190318 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190813 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20190820 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191007 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6600637 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |